Pharma channel feed – Endpoints News

Pharma channel feed

The (new) top 10 pharma companies by 2017 revenue

8 years ago

Is biopharma’s first $1.5M therapy now in Phase III?

8 years ago

FDA promises Roche a snap decision on Tecentriq triple for frontline lung cancer as it falls even further behind Merck, Bristol-Myers

8 years ago

For shame: ‘Pharma Bro’ Shkreli is in prison, but Daraprim’s price is still high

8 years ago

In a comeback, Portola scores FDA accelerated approval for once-rejected Andexxa

8 years ago

Rejected: After paying $80M to acquire it, Mallinckrodt's jaundice drug snubbed by FDA's advisory committee

8 years ago

Sarepta’s eteplirsen spurned as European regulators turn thumbs down on controversial Duchenne MD drug

8 years ago

Merck doubles down on Moderna's mRNA cancer vaccines, paying $125M to partner on KRAS shared antigen strategy

8 years ago

Glass half empty: Achaogen receives split vote from FDA experts on lead antibiotic, shares plunge

8 years ago

FDA’s back-to-back punches against biosims from Celltrion, Novartis leave Roche’s big Rituxan franchise untouched

8 years ago

Kymriah wins second FDA OK, boosting hope for Novartis' low CAR-T sales

8 years ago

Roche boosts its gene therapy game, expanding partnership with 4D Molecular Therapeutics

8 years ago

Biogen tosses in an extra $50M for a bigger slice of the royalties for its PhIII Alzheimer’s drug aducanumab

8 years ago

Sanofi/Regeneron’s one-two punch on PCSK9 price and health data wins a key convert as Express Scripts creates exclusive formulary deal

8 years ago

Gilead joins the lineup of big biopharma partners to ally with Verily — this time focused on immunology

8 years ago

Spark's PRV draws lukewarm price, selling for $110M to Jazz

8 years ago

Regeneron/Sanofi circle October 28 on the calendar as the FDA begins a speedy review of the world’s 6th PD-1/L1 checkpoint

8 years ago

Ahead of Hong Kong listing changes, WuXi preps for a biotech boom with a new R&D center in Shanghai

8 years ago

Two more top FDA officials hit the exits as an exodus of senior regulators continues

8 years ago

Vertex's rapid-fire PhIII program hits a roadblock at the FDA. Will regulators force rival Galapagos to slow down too?

8 years ago

Acadia shares slide — again — after FDA confirms it has launched a safety review of Nuplazid

8 years ago

Celldex brings out the ax in wake of breast cancer drug disaster, chopping a quarter of its staff

8 years ago

'Site-less' trials in mind, Novartis launches an app for ophthalmology research

8 years ago

Can Takeda actually close its $65B deal to buy Shire? Maybe, but analysts aren't sure they should

8 years ago

First page Previous page 298 299 300301302 303 304 Next page Last page